Literature DB >> 11679085

Accumulation of calbindin in cortical pyramidal cells with ageing; a putative protective mechanism which fails in Alzheimer's disease.

J R Greene1, N Radenahmad, G K Wilcock, J W Neal, R C Pearson.   

Abstract

There is considerable interest in the status of calbindin immunoreactive neurones in Alzheimer's disease (AD) but previous studies have produced widely differing results. Here we describe calbindin neurones in temporal neocortex from 18 severely demented patients with neuropathologically confirmed AD and 13 age and post-mortem delay matched, neurologically normal controls. Calbindin immunoreactive neurones were small and round in layers II-IV, and pyramidal in layers IIIc and V. There were significantly more calbindin positive neurones in controls than in AD (mean+/- SD, for each comparison P < 0.01): superior temporal lobe, AD = 3.32 +/- 2.24, Control (C) = 24.83 +/- 10.8; middle temporal lobe, AD = 3.6 +/- 4.94, C = 26.09 +/- 15.7; inferior temporal lobe, AD 3.69 +/- 3.6, C = 25.25 +/- 16.9. Furthermore, there was an age-related increase in immunopositive neurones in the superior (r2 = 0.37, P = 0.046) and inferior (r2 = 0.75, P = 0.01) temporal gyri in controls. In AD the number of calbindin positive neurones did not change with age. This is the first report of such an age-related increase in controls, and it suggests that this, rather than a decrease in AD, accounts for the overall difference between AD and controls. It is possible that an increase in intraneuronal calbindin protects these cells from degeneration and that failure of such a neuroprotective mechanism is a significant contributory factor in the pathogenesis of AD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11679085     DOI: 10.1046/j.0305-1846.2001.00351.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  6 in total

1.  Meta-analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability.

Authors:  Martijn C de Wilde; Cassia R Overk; John W Sijben; Eliezer Masliah
Journal:  Alzheimers Dement       Date:  2016-01-14       Impact factor: 21.566

2.  Reduced secretagogin expression in the hippocampus of P301L tau transgenic mice.

Authors:  Johannes Attems; Arne Ittner; Kurt Jellinger; Roger M Nitsch; Magdalena Maj; Ludwig Wagner; Jürgen Götz; Mathias Heikenwalder
Journal:  J Neural Transm (Vienna)       Date:  2011-03-26       Impact factor: 3.575

3.  Cerebrospinal Fluid Calbindin D Concentration as a Biomarker of Cerebellar Disease Progression in Niemann-Pick Type C1 Disease.

Authors:  Allison Bradbury; Jessica Bagel; Maureen Sampson; Nicole Farhat; Wenge Ding; Gary Swain; Maria Prociuk; Patricia O'Donnell; Kenneth Drobatz; Brittney Gurda; Christopher Wassif; Alan Remaley; Forbes Porter; Charles Vite
Journal:  J Pharmacol Exp Ther       Date:  2016-06-15       Impact factor: 4.402

4.  Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis.

Authors:  Rebecca Craig-Schapiro; Max Kuhn; Chengjie Xiong; Eve H Pickering; Jingxia Liu; Thomas P Misko; Richard J Perrin; Kelly R Bales; Holly Soares; Anne M Fagan; David M Holtzman
Journal:  PLoS One       Date:  2011-04-19       Impact factor: 3.240

5.  Crucial role of calbindin-D28k in the pathogenesis of Alzheimer's disease mouse model.

Authors:  S-Y Kook; H Jeong; M J Kang; R Park; H J Shin; S-H Han; S M Son; H Song; S H Baik; M Moon; E C Yi; D Hwang; I Mook-Jung
Journal:  Cell Death Differ       Date:  2014-05-23       Impact factor: 15.828

6.  Design and Experimental Evaluation of a Peptide Antagonist against Amyloid β(1-42) Interactions with Calmodulin and Calbindin-D28k.

Authors:  Jairo Salazar; Joana Poejo; Ana M Mata; Alejandro K Samhan-Arias; Carlos Gutierrez-Merino
Journal:  Int J Mol Sci       Date:  2022-02-18       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.